Editorial Board About Us

J Curtis Nickel

All articles from this author are listed below.

Volume 6, Supplement 9 Supplement

Comparison of Clinical Trials With Finasteride and Dutasteride

J Curtis Nickel

Benign prostatic hyperplasia Medical therapy Finasteride Dutasteride Dihydrotestosterone 5-reductase

Volume 6, Number 4 Meeting Reviews

Interstitial Cystitis: The Paradigm Shifts

International Consultations on Interstitial Cystitis

J Curtis Nickel

Biomarkers Interstitial cystitis Painful bladder syndrome Cystoscopy Chronic pelvic pain Symptom questionnaires

Volume 7, Number 4 Meeting Reviews

Best of the SIU Meeting on Prostatic Disease

Meeting Review

J Curtis Nickel

Prostate cancer Lower urinary tract symptoms Prostate-specific antigen Erectile dysfunction Prostatitis Benign prostatichyperplasia Prostate Cancer Prevention Trial

Volume 7, Supplement 8 Review Articles

a-Blockers for Treatment of the Prostatitis Syndromes

J Curtis Nickel

Benign prostatic hyperplasia Lower urinary tract symptoms Blockers

Volume 7, Number 1 Review Articles

Practical Management of Recurrent Urinary Tract Infections in Premenopausal Women

J Curtis Nickel

Cystitis Antimicrobial therapy Urinary tract infection (UTI)Antibioticprophylaxis Urinalysis Nitrofurantoin

Volume 7, Number 1 Literature Reviews

J Curtis Nickel

Volume 8, Supplement 4 Review Articles

Alpha-Blockers for the Treatment of Prostatitis-Like Syndromes

Advances in Alpha-Blocker Therapy in the Management of Urological Disorders

J Curtis Nickel

Prostatitis is a common medical diagnosis. The etiology of this symptomatic syndrome can be an acute or chronic bacterial infection, a noninfectious initiator (the most common cause), or iatrogenic heat or radiation; the syndrome may coexist with benign prostatic hyperplasia. Alpha-blockers have a role in the treatment of the prostatitis syndromes. In Category I, acute bacterial prostatitis, a-blockers have been shown to possibly ameliorate obstructive and irritative voiding symptoms. In Category II, chronic bacterial prostatitis, a-blockers seem to reduce the risk of clinical and bacteriological recurrence. In Category III, chronic pelvic pain syndrome, a-blockers improve symptoms and quality of life. Alpha-blockers also seem to ameliorate the symptoms and reduce the risk of acute urinary retention in patients who suffer from either heat- or radiation-induced prostatic inflammation. Alpha-blockers improve lower urinary tract symptoms, including pain, in patients who are diagnosed with both prostatitis and benign prostatic hyperplasia. Evidence has proven there is definitely a role for a-blockers in the management of the prostatitis syndromes. [Rev Urol. 2006;8(suppl 4):S26-S34]

Benign prostatic hyperplasia Lower urinary tract symptoms Blockers Prostatitis syndromes CP/CPPS

Volume 8, Number 3 Meeting Reviews

Best of the 2006 AUA Annual Meeting

Meeting Review

Michael K Brawer Arie S Belldegrun John P Stein John P Mulhall Tobias Klatte Michael E Aldridge Li-Ming Su Shachi Tyagi Danil V Makarov Ellen Shapiro Alan W Partin Michael B Chancellor Victor W Nitti J Curtis Nickel Jacob Rajfer Claus G Roehrborn

Highlights from the 2006 Annual Meeting of the American Urological Association May 20–25, 2006 Atlanta, GA

Prostate cancer Infertility Benign prostatic hyperplasia Bladder cancer Kidney cancer Lower urinary tract symptoms Bladder exstrophy Overactive bladder Interstitial cystitis Stress urinary incontinence Peyronie’s disease Spina bifida Neurogenic bladder Erectile dysfunction Chronic pelvic pain syndrome Chronic prostatitis Tumor markers Androgen replacement therapy Ejaculatory dysfunction Anorectal malformations Renal stones Robotic-assisted radical prostatectomy